Eli Lilly achieves success with Taltz Phase 3 study

Eli Lilly is set to seek regulatory approval for its new Ankylosing Spondylitis (AS) treatment Taltz after it performed well in a Phase 3 trial.

Taltz achieved the company's primary and secondary points in the study, which included a placebo arm and an active control arm (adalimumab) for comparison.

Researchers studied patients who had not received a biologic disease-modifying anti-rheumatic drug (bDMARD) and found that Taltz demonstrated a statistically significant improvement in the signs and symptoms of AS.

Dr Lotus Mallbris, vice-president and immunology platform team leader at Lilly Bio-Medicines, commented: "Many people with this chronic, debilitating disease are still searching for an effective treatment. 

"These initial results suggest that Taltz, if approved for this indication, may have the potential to help people with this challenging disease."

Dr Mallbris added that the unmet needs of people living with autoimmune diseases drive the firm's  commitment to investing in innovative therapies that may reduce the burden of illness and "aim to raise the bar for treatment expectations".

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.